Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

ASH 2010: new drugs and novel therapeutic concepts on the move

ASH 2010: new drugs and novel therapeutic concepts on the move editorial memo (2011) Vol. 4: 62–63 DOI 10.1007/s12254-011-0270-7 Printed in Austria © Springer-Verlag 2011 ASH 2010: new drugs and novel therapeutic concepts on the move M. Steurer Michael Steurer, M.D. Department of Internal Medicine V, Laboratory for Molecular Genetics & Diagnostics, Innsbruck Medical University, Innsbruck, Austria Received 17 April 2011; accepted 19 April 2011 Th e 52nd Annual Meeting of the American Society of Hema- this issue of memo distinct experts in the fi eld have taken on tology (ASH) which took place from December 3rd to 7th the task of working through the data to present a (subjective) 2010 in Orlando/Florida was attended by more than 20,000 selection of the most interesting and clinically relevant data participants. Over 3,000 presentations comprised the data for clinical decision making in the future. from out of >5000 abstracts. Th us, for attendees and non-at- Overall, the emphasis at ASH 2010 was not on large tendees alike it is obviously challenging to extract the most practice-changing clinical trials but rather on the continuing relevant data out of this wealth of information. Th erefore, in progress in basic science and early clinical studies exploring novel therapeutic concepts and/or new drugs. Correspondence: Michael Steurer, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

ASH 2010: new drugs and novel therapeutic concepts on the move

Download PDF
2 pages

Loading next page...
 
/lp/springer-journals/ash-2010-new-drugs-and-novel-therapeutic-concepts-on-the-move-UPE0RH0l7T
Publisher
Springer Journals
Copyright
Copyright © 2011 by Springer-Verlag
Subject
Medicine & Public Health; Medicine/Public Health, general; Oncology
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-011-0270-7
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2011) Vol. 4: 62–63 DOI 10.1007/s12254-011-0270-7 Printed in Austria © Springer-Verlag 2011 ASH 2010: new drugs and novel therapeutic concepts on the move M. Steurer Michael Steurer, M.D. Department of Internal Medicine V, Laboratory for Molecular Genetics & Diagnostics, Innsbruck Medical University, Innsbruck, Austria Received 17 April 2011; accepted 19 April 2011 Th e 52nd Annual Meeting of the American Society of Hema- this issue of memo distinct experts in the fi eld have taken on tology (ASH) which took place from December 3rd to 7th the task of working through the data to present a (subjective) 2010 in Orlando/Florida was attended by more than 20,000 selection of the most interesting and clinically relevant data participants. Over 3,000 presentations comprised the data for clinical decision making in the future. from out of >5000 abstracts. Th us, for attendees and non-at- Overall, the emphasis at ASH 2010 was not on large tendees alike it is obviously challenging to extract the most practice-changing clinical trials but rather on the continuing relevant data out of this wealth of information. Th erefore, in progress in basic science and early clinical studies exploring novel therapeutic concepts and/or new drugs. Correspondence: Michael Steurer,

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jun 30, 2011

References

  • Novel agents in diffuse large B-cell lymphoma
    Melchardt, T; Hofbauer, SW; Greil, R; Hopfinger, G
  • Chronic Lymphocytic Leukemia (CLL)
    Steurer, M; Schmidt, S
  • Indolent lymphoma and mantle cell lymphoma
    Drach, J
  • Novel developments in AML
    Sperr, W; Valent, P
  • Myelodysplastic Syndromes (MDS)
    Nösslinger, T; Pfeilstöcker, M
  • What's new in CML?
    Rudzki, J; Wolf, D
  • Multiple myeloma – Some points that Might change our daily practice
    Gunsilius, E; Willenbacher, W